ICML 2017 | ADCT-402 – a drug to watch

Brad Kahl • 14 Jun 2017

ICML 2017

Non-Hodgkin Lymphoma Loncastuximab tesirine

Brad Kahl, MD from University of Washington, St Louis, MO provides an overview from the trial he presented at the International Conference on Malignant Lymphoma (ICML) 2017 held in Lugano, Switzerland. The Phase I study (NCT02669017) is looking at ADCT-402, a novel pyrrolobenzodiazepine based antibody drug conjugate in relapsed/refractory B-cell lineage non Hodgkin lymphoma (NHL). The preliminary results have been very encouraging in terms of response rates and complete remission. The next stage will involve an expansion into a Phase II trial. Dose and scheduling optimization still needs to be carried out to detect thresholds of efficacy and toxicity. Prof. Kaht envisions that this drug will be particularly beneficial for those patients who are transplant ineligible.